5.6(top 5%)
impact factor
2.5K(top 10%)
99.6K(top 5%)
133(top 5%)
5.8(top 5%)
extended IF
all documents
doc citations
190(top 5%)

Top Articles

1Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs2005921
2Internet AddictionCNS Drugs2008568
3Pharmacological and Therapeutic Properties of ValproateCNS Drugs2002561
4Arterial Stiffness and Stroke in HypertensionCNS Drugs2005559
5Basic Pharmacology of ValproateCNS Drugs2002556
6Neuropsychiatric Adverse Effects of Interferon-??CNS Drugs2005422
7Cognitive Effects of Long-Term Benzodiazepine UseCNS Drugs2004420
8Intranasal Insulin as a Treatment for Alzheimer’s Disease: A Review of Basic Research and Clinical EvidenceCNS Drugs2013402
9Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of SchizophreniaCNS Drugs2006385
10Getting into the BrainCNS Drugs2009371
11The Role of Insulin Resistance in the Pathogenesis of Alzheimer??s DiseaseCNS Drugs2003366
12Adverse Effects of Atypical AntipsychoticsCNS Drugs2007364
13Sleep Disturbances in Patients with SchizophreniaCNS Drugs2008360
14Frontotemporal Lobar DegenerationCNS Drugs2010353
15Suicidal Behaviour in Bipolar DisorderCNS Drugs2003342
16Potential Mechanisms of Action of Lithium in Bipolar DisorderCNS Drugs2013337
17Smoking Cessation in WomenCNS Drugs2001335
18TianeptineCNS Drugs2001308
19Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the BrainCNS Drugs2017304
20Mechanism of Action of St John???s Wort in DepressionCNS Drugs2003301
21Toward a New Understanding of Attention-Deficit Hyperactivity Disorder PathophysiologyCNS Drugs2009300
22Antiepileptic Drugs in Non-Epilepsy DisordersCNS Drugs2008293
23ZolpidemCNS Drugs2005289
24Dopamine Partial AgonistsCNS Drugs2004285
25A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy SubjectsCNS Drugs2018284
26Neurobiological and Clinical Effects of the Antidepressant TianeptineCNS Drugs2008281
27Sleep Disturbances in Patients with Post-Traumatic Stress DisorderCNS Drugs2006275
28??-1 Receptor LigandsCNS Drugs2004266
29BlonanserinCNS Drugs2010263
30Benzodiazepines and Risk of Hip Fractures in Older PeopleCNS Drugs2003257
31The Mechanism of Action of Interferon-β in Relapsing Multiple SclerosisCNS Drugs2011257
32The Role of Memantine in the Treatment of Psychiatric Disorders Other Than the DementiasCNS Drugs2012257
33Withdrawing Benzodiazepines in Primary CareCNS Drugs2009255
34Clinical Relevance of Brain Volume Measures in Multiple SclerosisCNS Drugs2014254
35Effects of Newer Antipsychotics on Extrapyramidal FunctionCNS Drugs2002251
36Propofol: A Review of its Role in Pediatric Anesthesia and SedationCNS Drugs2015251
37Oxidative Damage and SchizophreniaCNS Drugs2001250
38Serotonin 5-HT1A Receptors as Targets for Agents to Treat Psychiatric Disorders: Rationale and Current Status of ResearchCNS Drugs2013245
39Venlafaxine Extended-ReleaseCNS Drugs2001242
40A Pooled Analysis of Lacosamide Clinical Trial Data Grouped by Mechanism of Action of Concomitant Antiepileptic DrugsCNS Drugs2010238
41The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive ReviewCNS Drugs2014238
42Psychogenic ExcoriationCNS Drugs2001237
43Residual Effects of HypnoticsCNS Drugs2004237
44RamelteonCNS Drugs2005236
45Sleep Disturbances in Patients with Alzheimer??s DiseaseCNS Drugs2001231
46Selectivity of Cholinesterase InhibitionCNS Drugs1999230
47Antipsychotic-Induced Weight Gain in Chronic and First-Episode Psychotic DisordersCNS Drugs2008229
48Ziprasidone in the Management of SchizophreniaCNS Drugs2003227
49Pharmacotherapy of Essential TremorCNS Drugs2008226
50The Hippocampus, Neurotrophic Factors and DepressionCNS Drugs2011221